Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy. It presents with a course of progression which may be slow and steady or step-wise or relapsing. Sensory ataxic polyneuropathy may be the only clinical manifestation of this disease. Treatment with interferon beta1a (INF beta1a) has been tried with different results in patients who were refractory to other, more conventional, immunomodulatory therapies. Here we report on a patient who had a relapsing form of pure sensory ataxic CIDP and who failed to respond to intravenous human immunoglobulin. He was put on INF beta1a for 3 years. During this period he suffered no relapses while his condition stabilized.
Villa
Andrés Maria
AM
División Neurología, Hospital Ramos Mejia, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. avilla@fmed.uba.ar
Garcea
Orlando
O
Di Egidio
Marianna
M
Saizar
Roberto
R
Sica
Roberto Eduardo Pedro
RE
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a